Profile data is unavailable for this security.
About the company
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
- Revenue in USD (TTM)30.99m
- Net income in USD-141.41m
- Incorporated2003
- Employees165.00
- LocationMarinus Pharmaceuticals IncThree Radnor Corporate Center100 Matsonford Rd, Suite 304RADNOR 19087United StatesUSA
- Phone+1 (484) 801-4670
- Fax+1 (302) 655-5049
- Websitehttps://marinuspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 76.50m | 2.00 | -- | 11.79 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
AN2 Therapeutics Inc | 0.00 | -64.73m | 77.26m | 41.00 | -- | 0.6177 | -- | -- | -2.82 | -2.82 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -53.65 | -- | -58.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
Cognition Therapeutics Inc | 0.00 | -25.79m | 79.68m | 25.00 | -- | 2.62 | -- | -- | -0.8564 | -0.8564 | 0.00 | 0.7609 | 0.00 | -- | -- | 0.00 | -60.26 | -- | -76.27 | -- | -- | -- | -- | -- | -- | -1,878.67 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Alpha Teknova Inc | 36.68m | -36.78m | 80.83m | 210.00 | -- | 0.8971 | -- | 2.20 | -1.17 | -1.17 | 1.15 | 2.21 | 0.2612 | 2.21 | 8.94 | 174,685.70 | -26.19 | -- | -28.17 | -- | 28.07 | -- | -100.26 | -- | 3.84 | -37.45 | 0.1283 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
Marinus Pharmaceuticals Inc | 30.99m | -141.41m | 81.30m | 165.00 | -- | 4.82 | -- | 2.62 | -2.63 | -2.63 | 0.5766 | 0.3072 | 0.144 | 1.55 | 6.11 | 187,812.10 | -65.70 | -49.64 | -77.53 | -57.76 | 93.76 | -- | -456.31 | -518.96 | 4.01 | -14.97 | 0.8132 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
Personalis Inc | 73.48m | -108.30m | 81.42m | 223.00 | -- | 0.6201 | -- | 1.11 | -2.25 | -2.25 | 1.53 | 2.56 | 0.2838 | 5.80 | 4.28 | 329,511.20 | -41.83 | -28.84 | -49.51 | -34.72 | 24.78 | 28.65 | -147.38 | -96.01 | 2.89 | -- | 0.0218 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 82.08m | 10.00 | -- | 14.35 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | -- | -184.22 | -- | -404.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Tempest Therapeutics Inc | 0.00 | -29.49m | 82.87m | 17.00 | -- | 3.07 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Aileron Therapeutics Inc | 0.00 | -15.73m | 83.51m | 15.00 | -- | 2.80 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
MDxHealth SA - ADR | -100.00bn | -100.00bn | 85.41m | 258.00 | -- | -- | -- | -- | -- | -- | -- | -0.0357 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.53 | -- | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
LifeVantage Corp | 205.45m | 3.60m | 85.98m | 248.00 | 24.21 | 3.21 | 11.82 | 0.4185 | 0.2796 | 0.2796 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
Holder | Shares | % Held |
---|---|---|
Suvretta Capital Management LLCas of 31 Dec 2023 | 5.35m | 9.78% |
Eventide Asset Management LLCas of 31 Dec 2023 | 4.53m | 8.29% |
Tang Capital Management LLCas of 16 Apr 2024 | 4.50m | 8.24% |
Franklin Advisers, Inc.as of 31 Dec 2023 | 3.83m | 7.02% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.77m | 6.91% |
Cormorant Asset Management LPas of 31 Dec 2023 | 3.25m | 5.95% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 3.15m | 5.77% |
Jennison Associates LLCas of 31 Mar 2024 | 2.97m | 5.43% |
Adage Capital Management LPas of 31 Dec 2023 | 2.58m | 4.72% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.57m | 4.71% |